Nonetheless, other researchers such as Metro et al. suggest that KRAS mutation appears to negatively affect sensitivity to first‐line platinum‐based chemotherapy in patients with advanced nonsquamous and EGFR wild‐type NSCLC, including ORR, disease control rate (DCR) and survival. Here, EGFR is linked to non-small cell lung carcinoma.